Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT05032196




Registration number
NCT05032196
Ethics application status
Date submitted
18/08/2021
Date registered
2/09/2021
Date last updated
14/11/2023

Titles & IDs
Public title
Study of WVE-003 in Patients With Huntington's Disease
Scientific title
A Multicenter, Randomized, Double-blind, Placebo Controlled, Phase 1b/2a Study of WVE-003 Administered Intrathecally in Patients With Huntington's Disease (SELECT-HD)
Secondary ID [1] 0 0
WVE-003-001
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Huntington Disease 0 0
Condition category
Condition code

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - WVE-003

Experimental: WVE-003 (Dose A) or placebo -

Experimental: WVE-003 (Dose B) or placebo -

Experimental: WVE-003 (Dose C) or placebo -


Treatment: Drugs: WVE-003
WVE-003 is a stereopure antisense oligonucleotide (ASO)
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Safety: Proportion of patients with adverse events (AEs)
Timepoint [1] 0 0
Day 1 through end of study (minimum of 36 weeks)
Secondary outcome [1] 0 0
Maximum concentration (Cmax) of WVE-003 in plasma
Timepoint [1] 0 0
Day 1 through end of study (minimum of 36 weeks)
Secondary outcome [2] 0 0
Area under the plasma concentration time curve for WVE-003 from time 0 to last quantifiable concentration (AUC0-t)
Timepoint [2] 0 0
Day 1 through end of study (minimum of 36 weeks)
Secondary outcome [3] 0 0
Terminal half-life (t1/2) of WVE-003 in cerebrospinal fluid (CSF)
Timepoint [3] 0 0
Day 1 through end of study (minimum of 36 weeks)

Eligibility
Key inclusion criteria
1. Presence of the A variant of SNP3 on the same allele as the pathogenic CAG triplet
expansion

2. Ambulatory, male or female patients aged =25 to =60 years

3. Clinical diagnostic motor features of HD, defined as Unified Huntington's Disease
Rating Scale (UHDRS) Diagnostic Confidence Score = 4

4. UHDRS Total Functional Capacity Scores =9 and =13
Minimum age
25 Years
Maximum age
60 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
1. Malignancy or received treatment for malignancy, other than treated basal cell or
squamous cell carcinoma of the skin, within the previous 5 years

2. Received any other study drug, including an investigational oligonucleotide, within
the past 1 year or 5 half-lives of the drug, whichever is longer, with the exception
of the following:

a. Received WVE-120101 or WVE-120102 within the last 3 months

3. Implantable CNS device that may interfere with ability to administer study drug via
lumbar puncture or undergo MRI scan

4. Inability to undergo brain MRI (with or without sedation)

5. Bone, spine, bleeding, or other disorder that exposes the patient to risk of injury or
unsuccessful lumbar puncture

6. Previously received tominersen

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s


The people analysing the results/data
Intervention assignment
Other
Other design features
Phase
Phase 1/Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
6/09/2021
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
1/12/2024
Actual
Sample size
Target
54
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW,VIC
Recruitment hospital [1] 0 0
Westmead Hospital - Westmead
Recruitment hospital [2] 0 0
Monash Health - Clayton
Recruitment hospital [3] 0 0
Royal Melbourne Hospital - Melbourne
Recruitment postcode(s) [1] 0 0
2145 - Westmead
Recruitment postcode(s) [2] 0 0
3168 - Clayton
Recruitment postcode(s) [3] 0 0
3050 - Melbourne
Recruitment outside Australia
Country [1] 0 0
Canada
State/province [1] 0 0
Alberta
Country [2] 0 0
Canada
State/province [2] 0 0
Ontario
Country [3] 0 0
Canada
State/province [3] 0 0
Quebec
Country [4] 0 0
Denmark
State/province [4] 0 0
Copenhagen
Country [5] 0 0
France
State/province [5] 0 0
Créteil
Country [6] 0 0
France
State/province [6] 0 0
Paris
Country [7] 0 0
Germany
State/province [7] 0 0
Bochum
Country [8] 0 0
Germany
State/province [8] 0 0
Muenster
Country [9] 0 0
Germany
State/province [9] 0 0
Taufkirchen
Country [10] 0 0
Italy
State/province [10] 0 0
Verona
Country [11] 0 0
Netherlands
State/province [11] 0 0
Leiden
Country [12] 0 0
Netherlands
State/province [12] 0 0
Maastricht
Country [13] 0 0
Poland
State/province [13] 0 0
Gdansk
Country [14] 0 0
Poland
State/province [14] 0 0
Warsaw
Country [15] 0 0
Spain
State/province [15] 0 0
Barcelona
Country [16] 0 0
Spain
State/province [16] 0 0
Madrid
Country [17] 0 0
United Kingdom
State/province [17] 0 0
Devon
Country [18] 0 0
United Kingdom
State/province [18] 0 0
Glasgow City
Country [19] 0 0
United Kingdom
State/province [19] 0 0
Wales
Country [20] 0 0
United Kingdom
State/province [20] 0 0
Liverpool

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Wave Life Sciences Ltd.
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This is a Phase 1b/2a multicenter, randomized, double-blind, placebo-controlled study to
evaluate the safety, tolerability, PK, and PD of WVE-003 in adult patients with
early-manifest HD who carry the targeted single nucleotide polymorphism (SNP) - SNP3.
Trial website
https://clinicaltrials.gov/ct2/show/NCT05032196
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Medical Director, MD
Address 0 0
Wave Life Sciences
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Clinical Operations
Address 0 0
Country 0 0
Phone 0 0
855-215-4687
Fax 0 0
Email 0 0
[email protected]
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT05032196